Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Bought by J. Safra Sarasin Holding AG

J. Safra Sarasin Holding AG grew its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 69.8% in the fourth quarter, Holdings Channel.com reports. The fund owned 19,142 shares of the biopharmaceutical company’s stock after purchasing an additional 7,868 shares during the period. J. Safra Sarasin Holding AG’s holdings in Alnylam Pharmaceuticals were worth $4,504,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in ALNY. Tidal Investments LLC boosted its holdings in Alnylam Pharmaceuticals by 75.1% in the third quarter. Tidal Investments LLC now owns 20,544 shares of the biopharmaceutical company’s stock valued at $5,650,000 after acquiring an additional 8,811 shares during the last quarter. American Trust acquired a new position in Alnylam Pharmaceuticals in the third quarter worth about $309,000. Versant Capital Management Inc boosted its holdings in Alnylam Pharmaceuticals by 77.6% in the fourth quarter. Versant Capital Management Inc now owns 190 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 83 shares during the period. Everence Capital Management Inc. acquired a new stake in Alnylam Pharmaceuticals during the fourth quarter worth about $593,000. Finally, Nordea Investment Management AB grew its position in shares of Alnylam Pharmaceuticals by 6.7% during the fourth quarter. Nordea Investment Management AB now owns 10,188 shares of the biopharmaceutical company’s stock worth $2,417,000 after acquiring an additional 637 shares during the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ:ALNY opened at $232.75 on Tuesday. Alnylam Pharmaceuticals, Inc. has a 1-year low of $141.98 and a 1-year high of $304.39. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27. The stock has a market cap of $30.28 billion, a PE ratio of -107.26 and a beta of 0.30. The stock’s fifty day simple moving average is $248.47 and its two-hundred day simple moving average is $256.64.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.03). As a group, analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CMO Pushkal Garg sold 1,548 shares of the firm’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $251.67, for a total value of $389,585.16. Following the completion of the transaction, the chief marketing officer now directly owns 11,989 shares of the company’s stock, valued at $3,017,271.63. This trade represents a 11.44 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Jeffrey V. Poulton sold 967 shares of Alnylam Pharmaceuticals stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $255.17, for a total value of $246,749.39. Following the sale, the chief financial officer now owns 32,786 shares of the company’s stock, valued at approximately $8,366,003.62. This trade represents a 2.86 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 71,234 shares of company stock valued at $19,958,097. 1.50% of the stock is owned by insiders.

Analyst Ratings Changes

ALNY has been the topic of a number of research analyst reports. Scotiabank raised their price objective on shares of Alnylam Pharmaceuticals from $338.00 to $342.00 and gave the company a “sector outperform” rating in a research note on Monday, March 31st. Stifel Nicolaus raised their price objective on Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the stock a “buy” rating in a research report on Monday, March 31st. Needham & Company LLC reiterated a “buy” rating and set a $320.00 price objective on shares of Alnylam Pharmaceuticals in a report on Wednesday, April 9th. Morgan Stanley lowered their target price on shares of Alnylam Pharmaceuticals from $284.00 to $268.00 and set an “equal weight” rating on the stock in a research report on Friday, April 11th. Finally, Redburn Atlantic assumed coverage on shares of Alnylam Pharmaceuticals in a research note on Monday, March 31st. They issued a “buy” rating and a $353.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty-one have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $315.58.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.